Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. When considering the Catalent Inc stock dividend history, we have taken known splits into account, such that the CTLT dividend history is presented on a split-adjusted ("apples to apples") basis. Catalent Inc dividend history is presented both in graphical/chart form, and as a CTLT dividend history data table along the right-hand column.
|
CTLT Stock Dividend HistoryThe CTLT dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable CTLT historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the CTLT dividend history record. Also see the CTLT stock dividend history data table along the right-hand column below. |
|
|
Hold (2.40 out of 4) 9th percentile
(ranked lower than approx. 91% of all stocks covered)
Analysts' Target Price: CTLT Forecast Based on data provided by Zacks Investment Research via Quandl.com |